3 results about "Glycol methacrylate" patented technology

This invention discloses a method for preparing an aqueous thermosensitive Cr(III) ion-imprinted polymer, belonging to the field of water pollution treatment technology. The method includes the following steps: (1) dissolving aminated multi-walled carbon nanotubes and potassium carbonate in N,N-dimethylformamide, and adding bromopropylene to obtain vinylated multi-walled carbon nanotubes; (2) dissolving CrCl3·6H2O, a functional monomer, and a thermosensitive monomer in a porous solvent composed of ethanol and water, adding vinylated multi-walled carbon nanotubes, ethylene glycol dimethacrylate, and azobisisobutyronitrile to obtain the Cr(III) ion-imprinted polymer. This invention introduces the thermosensitive functional monomer N-isopropylacrylamide, enabling the ion-imprinted polymer to respond to changes in ambient temperature and accurately identify and adsorb target ions in complex environments. The introduction of the thermosensitive functional monomer allows the polymer to form a hydrophilic layer, reducing non-specific adsorption caused by impurities such as humic acid, and improving the adsorption capacity and selectivity for target ions.

The application relates to the technical field of biological separation engineering, and discloses a recombinant biomimetic affinity ligand for purifying bromelain as well as a preparation method and application of the recombinant biomimetic affinity ligand, which is prepared from the following raw materials in parts by weight: double-bonded silica-coated magnetic microspheres: 100 parts; monomer methyl acrylate: 150-250 parts; epoxy-containing monomer glycidyl methacrylate: 50-100 parts; crosslinking agent ethylene glycol dimethacrylate: 3-6 parts; and biomimetic affinity heptapeptide: 10-20 parts. The biomimetic affinity heptapeptide with a specific amino acid sequence is used as the affinity ligand, the hydrophobic residues and charged side chains in the sequence can specifically bind to the S2 sub-site and surrounding residues of the active center of bromelain to realize cavity complementation, high-specificity recognition of the target enzyme is realized, and the affinity medium prepared by using the ligand can effectively eliminate the interference of homologous impure proteins which are highly similar in structure and physicochemical properties.

The present invention relates to ocular compositions for the controlled release of a therapeutic agent. The ocular composition comprises at least 20% w / w of a therapeutic agent; 5 to 75% w / w of a photopolymerizable composition selected from the group consisting of fragments or monomers of polyalkylene glycol mono-acrylate, polyalkylene glycol diacrylate, polyalkylene glycol methacrylate and polyalkylene glycol dimethacrylate, and mixtures, copolymers, and block copolymers thereof; 0.1 to 40% w / w of a biodegradable polymer selected from the group consisting of lactide / glycolide copolymer (including poly(lactide-co-glycolide) (PLGA)), poly (L-lactide) (PLA), polyhydroxyalkanoates, including polyhydroxybutyrate, polyglycolic acid (PGA), polycaprolactone (PCL), poly (DL-lactide) (PDL), poly (D-lactide), lactide / caprolactone copolymer, poly-L-lactide-co-caprolactone (PLC) and mixtures, copolymers, and block copolymers thereof; and a photoinitiator.